3 results
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
Approved WMOPending
To evaluate the safety and efficacy of ravagalimab vs placebo for the treatment of primary Sjogren's syndrome (pSS) in subjects with moderately to severely active primary Sjogren's syndrome (pSS).
Approved WMORecruiting
The objective of this study is to evaluate the effectiveness of different treatments to prevent CME after cataract surgery, using either topical drugs (control group) or intra-/periocular injections (intervention groups).